The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
The transaction is expected to close in the first quarter of 2022
The brand is now available pan-India through their distribution partner
It is the generic version of molnupiravir
Subscribe To Our Newsletter & Stay Updated
